24/7 Market News Snapshot 04 September, 2025 – Purple Biotech Ltd. American Depositary Shares (NASDAQ:PPBT)
DENVER, Colo., 04 September, 2025 (www.247marketnews.com) – (NASDAQ:PPBT) are discussed in this article.
Purple Biotech Ltd. (NASDAQ/TASE: PPBT), a clinical-stage company dedicated to developing therapies that address tumor immune evasion and drug resistance, is facing a notable decline in its stock performance, trading at $0.907, which marks a significant 36.13% drop from the previous close of $1.420. This downturn is indicative of increased selling pressure, as evidenced by a trading volume of 33.14 million shares, highlighting robust investor activity. Technical analysis suggests that the stock may be oversold; however, further declines may occur if the prevailing bearish sentiment continues. Investors should remain vigilant on key support levels around $0.90 and resistance near $1.00, which could significantly influence future price trends in this volatile market environment.
Concurrently, the Company has announced a major public offering of its American Depositary Shares (ADSs), comprising 5,999,999 ADSs accompanied by short-term warrants allowing for the purchase of an additional 11,999,998 ADSs, all priced at $1.00 each. This initiative is expected to yield gross proceeds of approximately $6 million before fees and expenses, and if warrants are fully exercised, this could lead to a total gross revenue of about $12 million. The closing of this offering is anticipated around September 5, 2025, pending customary closing conditions.
The funds raised in this offering will be strategically allocated towards enhancing Purple Biotech’s oncology pipeline, fostering the development of advanced therapeutic candidates such as CAPTN-3, CM24, and NT219, while also supporting general operational needs. CAPTN-3, in particular, utilizes conditionally activated tri-specific antibodies designed to activate both T cells and natural killer cells, creating localized immune responses against tumors. H.C. Wainwright & Co. is serving as the exclusive placement agent for the offering, which is registered under Form F-1 recently approved by the SEC. This decisive step is integral to the Company’s mission of advancing transformative cancer treatments that aim to improve patient outcomes significantly.